|
Seth W. Hamot (age 45) has been a Class D director of the Company since June 18, 2007. He is managing member of Roark, Rearden & Hamot Capital Management, LLC (RRHCM), and owner of Roark, Rearden & Hamot, Inc. (RRHI), since 1997, and President of Roark, Rearden & Hamot, LLC (RRH) since 2002. Mr. Hamot was nominated for election by Costa Brava Partnership III L.P. (Costa Brava), a holder of the Company’s Public Preferred Stock. Since 1997, Mr. Hamot has been the Managing Member of RRHCM and the owner of RRHI, the corporate predecessor of RRHCM. RRHCM is the investment manager to Costa Brava Partnership III LP, an investment fund, whose principal business is to make investments in, buy, sell, hold, pledge and assign securities. Mr. Hamot is also the President of RRH, the general partner of Costa Brava. Prior to 1997, Mr. Hamot was one of the partners of the Actionvest entities. Mr. Hamot is currently the Interim Non-executive Chairman of the Board of Bradley Pharmaceuticals Inc., a NYSE listed specialty pharmaceutical company, and serves as a member of that company’s audit committee. Mr. Hamot is also a Director of CCA Industries, Inc., an AMEX listed manufacturer of health and beauty aids, and serves as a member of the audit and compensation committees.
| 